Eledon Pharmaceuticals (ELDN) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 18, 2026, with voting on director elections, an amendment to increase authorized common stock, and auditor ratification.

• Board recommends voting for all proposals, including electing three Class III directors, increasing authorized shares, and ratifying Deloitte as auditor.

• Proxy materials and annual report are available online, with multiple voting methods offered.

Voting matters and shareholder proposals

• Proposal 1: Elect David-Alexandre C. Gros, Jan Hillson, and James Robinson as Class III directors for terms expiring in 2029.

• Proposal 2: Approve amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares.

• Proposal 3: Ratify Deloitte & Touche LLP as independent registered public accounting firm for 2026.

• Board unanimously recommends voting for all proposals.

• Shareholders may submit proposals for the 2027 annual meeting by specified deadlines.

Board of directors and corporate governance

• Board is classified into three staggered classes, with detailed biographies provided for all directors.

• Majority of directors are independent; CEO and President are not independent.

• Board committees include audit, compensation, nominating and corporate governance, and science and technology, all chaired by independent directors.

• Board held nine meetings in 2025, with high attendance.

• Board diversity includes two female and two racially/ethnically diverse directors.